logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hironobu Minami

medicine
H指数:55
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and biomarker analysis for nivolumab in cancer of unknown primary: results from an investigator-initiated expanded access program

纳武利尤单抗治疗未知原发灶癌症的疗效与生物标志物分析：来自研究者发起的扩展性准入项目的结果

International Journal of Clinical Oncology
IF2.8
2026-09-240
OAAI
Junko Tanizaki; Kan Yonemori; Yuichi Takiguchi; Kohei Akiyoshi; Keigo Komine; Yusuke Onozawa; Mariko Sato; Kenro Hirata; Takuma Onoe; Ryotaro Ohkuma; Yosuke Horita; Hironobu Minami; Kazunori Honda; Koichi Suyama; Akihiko Ito; Yasutaka Chiba; Hiroko Watanabe; Yosuke Togashi; Kazuko Sakai; Kazuto Nishio; Kazuhiko Nakagawa; Hidetoshi Hayashi
Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial

比较倍他司汀与氯雷他定在预防非霍奇金淋巴瘤患者利妥昔单抗诱导的输注相关反应中的疗效：一项II期、双盲、多中心、随机试验

International Journal of Clinical Oncology
IF2.8
2026-04-160
OAAI
Yumi Kitahiro; Hironobu Minami; Kazuhiro Yamamoto; Kimikazu Yakushijin; Keiji Kurata; Rina Sakai; Miki Saeki; Yuri Okazoe-Hirakawa; Kotaro Iida; Natsuko Murase; Isamu Harima; Naoko Kitamura; Kotaro Itohara; Tomohiro Omura; Takeshi Sugimoto; Hidetomo Takakura; Akihito Kitao; Masako Takahashi; Manabu Shimoyama; Mamoru Okuno; Ikuko Yano
A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer

一项关于纳武利尤单抗治疗铂类耐药的复发性或转移性唾液腺癌患者的II期临床试验

JAPANESE JOURNAL OF CLINICAL ONCOLOGY
IF2.2
2025-12-010
OA
Nagatani, Yoshiaki; Kiyota, Naomi; Yamazaki, Tomoko; Asada, Yukinori; Higashino, Masaaki; Satake, Hironaga; Boku, Shogen; Nishimura, Ari; Uemura, Hirokazu; Ota, Ichiro; Yane, Katsunari; Tanaka, Kaoru; Onoe, Takuma; Hirayama, Yuji; Tsujikawa, Takahiro; Fujiwara, Hajime; Shimoda, Hikari; Nibu, Ken-Ichi; Imamura, Yoshinori; Kimbara, Shiro; Koyama, Taiji; Funakoshi, Yohei; Minami, Hironobu
Long-term efficacy and safety of tucidinostat inpatients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results
HAEMATOLOGICA
IF7.9
2024-06-060
OAAI
Rai, Shinya; Kim, Won Seog; Ando, Kiyoshi; Choi, Ilseung; Izutsu, Koji; Tsukamoto, Norifumi; Maruyama, Dai; Tsukasaki, Kunihiro; Kuroda, Junya; Ando, Jun; Hidaka, Michihiro; Koh, Youngil; Kato, Hisashi; Uchida, Toshiki; Yang, Deok Hwan; Ishitsuka, Kenji; Ishizawa, Kenichi; Kim, Jin Seok; Lee, Hong Ghi; Minami, Hironobu; Eom, Hyeon Seok; Kurosawa, Mitsutoshi; Lee, Jae Hoon; Lee, Jong Seok; Lee, Won Sik; Nagai, Hirokazu; Shindo, Takero; Yoon, Dok Hyun; Yoshida, Shinichiro; Gillings, Mireille; Onogi, Hiroshi; Tobinai, Kensei
A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody

紫杉醇联合两周一次的西妥昔单抗治疗先前接受铂类化疗和anti-PD-1抗体治疗的复发或转移性头颈癌患者的II期试验

ESMO OPEN
IF8.3
2024-06-014
OAAI
Koyama, T.; Kiyota, N.; Boku, S.; Imamura, Y.; Shibata, N.; Satake, H.; Tanaka, K.; Hayashi, H.; Onoe, T.; Asada, Y.; Yamazaki, T.; Nose, T.; Ohata, S.; Nagatani, Y.; Kimbara, S.; Funakoshi, Y.; Teshima, M.; Shinomiya, H.; Minami, H.

研究方向

暂未获取到该数据
N
Naomi Kiyota
H 指数:44论文数:349被引数:1.4万
Y
Yoshinori Imamura
H 指数:24论文数:215被引数:3,048
T
Toru Mukohara
H 指数:32论文数:236被引数:5,852
Y
Yohei Funakoshi
H 指数:18论文数:109被引数:1,871
K
Kimikazu Yakushijin
H 指数:21论文数:275被引数:2,003
H
Hiroshi Matsuoka
H 指数:24论文数:301被引数:2,479
M
Masanori Toyoda
H 指数:19论文数:116被引数:2,453
Y
Yutaka Fujiwara
H 指数:42论文数:411被引数:6,691
K
Katsuya Yamamoto
H 指数:22论文数:173被引数:1,620
N
Naoko Chayahara
H 指数:19论文数:86被引数:1,903